Statement on the impact of coronavirus disease Covid-19 on our operations
At Fujirebio Europe’s Belgian facilities, we are taking steps to protect our employees, and encourage those who can do so to work from home. The manufacture of medical products is considered an essential service in Belgium, and our production, quality, and logistics staff continue to work as before. We have adequate inventories of raw materials to continue uninterrupted manufacturing operations of the INNO-LIA®, INNO-LiPA®, and INNOTEST® product lines for many months.
We do not foresee SERODIA® or Lumipulse® manufacturing shortfalls from our Japanese operation resulting from Covid-19-related shutdowns. However, the Covid-19 pandemic has resulted in unprecedented demand for lung, inflammation, and bacterial versus viral infection markers such as KL-6, IL-6, and PCT. In response, the manufacturing site in Japan has scheduled additional production batches of these Lumipulse assays. Please contact Order Handling for further details on product availability.
Fujirebio Europe plays a direct role in the fight against the Covid pandemic by offering a range of CE Marked Covid-19 assays. Included in this range is an RT-PCR assay manufactured by Atila Biosystems, an antigen test for the Lumipulse automated CLEIA analyzers, an antigen test in the ESPLINE® lateral flow ELISA format, and a series of microwell ELISAs for Covid-19 antibody.
Please note that we continue to observe the impact of Covid-19 on air freight. The cancellation of passenger flights that would normally also carry freight is limiting global air freight capacity. The result is that air freight is becoming progressively more complex and expensive.
Since our ability to ship product promptly by air is less certain than usual, we urge customers to anticipate their needs as far in advance as possible to better facilitate on-time delivery.
We wish all of our customers and their families good health during this unusual and challenging time.
Christiaan De Wilde
On behalf of CDW Invest BV